Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients

References

• Garcia M, Jemal A, Ward E, Center MM, Hao Y. Global Cancer Facts and Figures 2007. American Cancer Society 2007.
   Google Scholar
• Al-Eid HS. Cancer Incidence Report: Saudi Arabia. National Cancer Registry 2004.
   Google Scholar
• Porter P. “Westernizing” women’s risks? Breast cancer in lower-income countries. N Engl J Med 2008; 358:213 - 6; http://dx.doi.org/10.1056/NEJMp0708307; PMID: 18199859
   PubMed Web of Science ®Google Scholar
• Deramaudt T, Rustgi AK. Mutant KRAS in the initiation of pancreatic cancer. Biochim Biophys Acta 2005; 1756:97 - 101; PMID: 16169155
   PubMed Web of Science ®Google Scholar
• Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759 - 67; http://dx.doi.org/10.1016/0092-8674(90)90186-I; PMID: 2188735
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148 - 59; http://dx.doi.org/10.1056/NEJMra072067; PMID: 18337604
   PubMed Web of Science ®Google Scholar
• Warnecke PM, Bestor TH. Cytosine methylation and human cancer. Curr Opin Oncol 2000; 12:68 - 73; http://dx.doi.org/10.1097/00001622-200001000-00012; PMID: 10687732
   PubMed Web of Science ®Google Scholar
• Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006; 5:1597 - 601; http://dx.doi.org/10.4161/cc.5.15.3112; PMID: 16880743
   PubMed Web of Science ®Google Scholar
• Eng C, Leone G, Orloff MS, Ostrowski MC. Genomic alterations in tumor stroma. Cancer Res 2009; 69:6759 - 64; http://dx.doi.org/10.1158/0008-5472.CAN-09-0985; PMID: 19706759
   PubMed Web of Science ®Google Scholar
• Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655 - 7; http://dx.doi.org/10.1126/science.296.5573.1655; PMID: 12040186
   PubMed Web of Science ®Google Scholar
• Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7:606 - 19; http://dx.doi.org/10.1038/nrg1879; PMID: 16847462
   PubMed Web of Science ®Google Scholar
• Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318:1108 - 13; http://dx.doi.org/10.1126/science.1145720; PMID: 17932254
   PubMed Web of Science ®Google Scholar
• Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304:554 - 554; http://dx.doi.org/10.1126/science.1096502; PMID: 15016963
   PubMed Web of Science ®Google Scholar
• Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004; 3:772 - 5; http://dx.doi.org/10.4161/cbt.3.8.994; PMID: 15254419
   PubMed Web of Science ®Google Scholar
• Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006; 94:455 - 9; http://dx.doi.org/10.1038/sj.bjc.6602970; PMID: 16449998
   PubMed Web of Science ®Google Scholar
• Samuels Y, Diaz LA Jr., Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005; 7:561 - 73; http://dx.doi.org/10.1016/j.ccr.2005.05.014; PMID: 15950905
   PubMed Web of Science ®Google Scholar
• Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, et al. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A 2009; 106:2835 - 40; http://dx.doi.org/10.1073/pnas.0813351106; PMID: 19196980
   PubMed Web of Science ®Google Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9:550 - 62; http://dx.doi.org/10.1038/nrc2664; PMID: 19629070
   PubMed Web of Science ®Google Scholar
• Allison M. Is personalized medicine finally arriving?. Nat Biotechnol 2008; 26:509 - 17; http://dx.doi.org/10.1038/nbt0508-509; PMID: 18464779
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646 - 74; http://dx.doi.org/10.1016/j.cell.2011.02.013; PMID: 21376230
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10:789 - 99; http://dx.doi.org/10.1038/nm1087; PMID: 15286780
   PubMed Web of Science ®Google Scholar
• http://www.sanger.ac.uk/genetics/CGP/cosmic/
   Google Scholar
• Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010; 120:2858 - 66; http://dx.doi.org/10.1172/JCI37539; PMID: 20664172
   PubMed Web of Science ®Google Scholar
• Mohseni M, Park BH. PIK3CA and KRAS mutations predict for response to everolimus therapy: now that’s RAD001. J Clin Invest 2010; 120:2655 - 8; http://dx.doi.org/10.1172/JCI44026; PMID: 20664174
   PubMed Web of Science ®Google Scholar
• Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8:627 - 44; http://dx.doi.org/10.1038/nrd2926; PMID: 19644473
   PubMed Web of Science ®Google Scholar
• Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28:1075 - 83; http://dx.doi.org/10.1200/JCO.2009.25.3641; PMID: 20085938
   PubMed Web of Science ®Google Scholar
• Maira S-M, Finan P, Garcia-Echeverria C. From the bench to the bed side: PI3K pathway inhibitors in clinical development. Curr Top Microbiol Immunol 2010; 347:209 - 39; http://dx.doi.org/10.1007/82_2010_60; PMID: 20582534
   PubMed Web of Science ®Google Scholar
• Chavez-MacGregor M, Gonzalez-Angulo AM. Everolimus in the treatment of hormone receptor-positive breast cancer. Expert Opin Investig Drugs 2012; 21:1835 - 43; http://dx.doi.org/10.1517/13543784.2012.726218; PMID: 22994502
   PubMed Web of Science ®Google Scholar
• Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009; 15:5049 - 59; http://dx.doi.org/10.1158/1078-0432.CCR-09-0632; PMID: 19671852
   PubMed Web of Science ®Google Scholar
• Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, Ferro A, Dalla Palma P, Galligioni E, Marchetti A. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 2007; 13:6064 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-07-0266; PMID: 17947469
   PubMed Web of Science ®Google Scholar
• Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 2007; 13:408 - 14; http://dx.doi.org/10.1158/1078-0432.CCR-06-0267; PMID: 17202311
   PubMed Web of Science ®Google Scholar
• Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 2006; 96:91 - 5; http://dx.doi.org/10.1007/s10549-005-9048-0; PMID: 16317585
   PubMed Web of Science ®Google Scholar
• Lerma E, Catasus L, Gallardo A, Peiro G, Alonso C, Aranda I, Barnadas A, Prat J. Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas. Virchows Arch 2008; 453:133 - 9; http://dx.doi.org/10.1007/s00428-008-0643-4; PMID: 18679714
   PubMed Web of Science ®Google Scholar
• Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 2010; 107:10208 - 13; http://dx.doi.org/10.1073/pnas.0907011107; PMID: 20479250
   PubMed Web of Science ®Google Scholar
• Michelucci A, Di Cristofano C, Lami A, Collecchi P, Caligo A, Decarli N, Leopizzi M, Aretini P, Bertacca G, Porta RP, et al. PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases. Diagn Mol Pathol 2009; 18:200 - 5; http://dx.doi.org/10.1097/PDM.0b013e31818e5fa4; PMID: 19861897
   PubMed Web of Science ®Google Scholar
• Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65:2554 - 9; http://dx.doi.org/10.1158/0008-5472-CAN-04-3913; PMID: 15805248
   PubMed Web of Science ®Google Scholar
• Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Siraj AK, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, et al. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene 2008; 27:3539 - 45; http://dx.doi.org/10.1038/sj.onc.1211013; PMID: 18193083
   PubMed Web of Science ®Google Scholar
• Abubaker J, Bavi P, Al-Haqawi W, Jehan Z, Munkarah A, Uddin S, Al-Kuraya KS. PIK3CA alterations in Middle Eastern ovarian cancers. Mol Cancer 2009; 8:51; http://dx.doi.org/10.1186/1476-4598-8-51; PMID: 19638206
   PubMed Web of Science ®Google Scholar
• Cohen Y, Merhavi-Shoham E, Avraham-Lubin BCR, Savetsky M, Frenkel S, Pe’er J, Goldenberg-Cohen N. PI3K/Akt pathway mutations in retinoblastoma. Invest Ophthalmol Vis Sci 2009; 50:5054 - 6; http://dx.doi.org/10.1167/iovs.09-3617; PMID: 19420344
   PubMed Web of Science ®Google Scholar
• Goff LA, Davila J, Swerdel MR, Moore JC, Cohen RI, Wu H, Sun YE, Hart RP. Ago2 immunoprecipitation identifies predicted microRNAs in human embryonic stem cells and neural precursors. PLoS One 2009; 4:e7192; http://dx.doi.org/10.1371/journal.pone.0007192; PMID: 19784364
   PubMed Web of Science ®Google Scholar
• miRBase. http://www.mirbase.org/search.shtml
   Google Scholar
• Campbell I, Qiu W, Haviv I. Genetic changes in tumour microenvironments. J Pathol 2011; 223:450 - 8; http://dx.doi.org/10.1002/path.2842; PMID: 21294119
   PubMed Web of Science ®Google Scholar
• Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006; 5:1597 - 601; http://dx.doi.org/10.4161/cc.5.15.3112; PMID: 16880743
   PubMed Web of Science ®Google Scholar
• Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou X-P, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 2002; 32:355 - 7; http://dx.doi.org/10.1038/ng1013; PMID: 12379854
   PubMed Web of Science ®Google Scholar
• Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, Platzer P, Eng C. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 2007; 357:2543 - 51; http://dx.doi.org/10.1056/NEJMoa071825; PMID: 18094375
   PubMed Web of Science ®Google Scholar
• Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, Trivett M, Thompson ER, Ramakrishna M, Gorringe KL, et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 2008; 40:650 - 5; http://dx.doi.org/10.1038/ng.117; PMID: 18408720
   PubMed Web of Science ®Google Scholar
• Hosein AN, Wu M, Arcand SL, Lavallée S, Hébert J, Tonin PN, Basik M. Breast carcinoma-associated fibroblasts rarely contain p53 mutations or chromosomal aberrations. Cancer Res 2010; 70:5770 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-10-0673; PMID: 20570891
   PubMed Web of Science ®Google Scholar
• Hawsawi NM, Ghebeh H, Hendrayani S-F, Tulbah A, Al-Eid M, Al-Tweigeri T, Ajarim D, Alaiya A, Dermime S, Aboussekhra A. Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes. Cancer Res 2008; 68:2717 - 25; http://dx.doi.org/10.1158/0008-5472.CAN-08-0192; PMID: 18413739
   PubMed Web of Science ®Google Scholar